• Stephen R Broderick.
• Department of Surgery, Johns Hopkins Medical Institutions, 600 North Wolfe Street, Blalock 240, Baltimore, MD 21287, USA. Electronic address: sbroder7@jhmi.edu.
• Thorac Surg Clin. 2020 May 1; 30 (2): 215-220.

AbstractThe advent of immune checkpoint blockade has revolutionized the management of advanced non-small cell lung cancer (NSCLC). Impressive results in the metastatic setting have prompted substantial interest in the application of these agents in earlier-stage disease. Applications of checkpoint blockade in the adjuvant setting are under investigation in several clinical trials. Early trials have demonstrated the safety and feasibility of the administration of checkpoint inhibitors in the neoadjuvant setting. Resection specimens demonstrate encouraging rates of pathologic response. There are several ongoing phase 3 studies comparing neoadjuvant combination chemotherapy and checkpoint blockade to chemotherapy alone in patients with resectable NSCLC.Copyright © 2020 Elsevier Inc. All rights reserved.

23 keywords...

hide…